Strong Phase III Data Have Linaclotide On Track For Filing In 2011

Ironwood Pharmaceuticals and its partner, Forest Laboratories, announced Sept. 13 strong top-line results from a Phase III trial of linaclotide in irritable bowel syndrome with constipation (IBS-C) – an important signal of support for investors' confidence in the high-profile biotech.